Literature DB >> 8730788

The effect of riluzole on post-traumatic spinal cord injury in the rat.

J M Stutzmann1, J Pratt, T Boraud, C Gross.   

Abstract

This study evaluated treatment with riluzole, a neuroprotective agent, following thoracic spinal cord compression in the rat. Animals received riluzole (2 mg kg-1) or vehicle twice daily for 10 days following the trauma. Motor deficits, somatosensory evoked potentials (SEP) and lesion histology were evaluated. Although paralysis was seen following trauma, seven of 10 animals receiving riluzole recovered motor function and nearly normal behaviour, unlike animals receiving vehicle. Trauma dramatically disturbed SEPs with falls in amplitude and increases in latency. After riluzole SEP returned towards pre-injury levels, while untreated animals showed no recovery. Morphological studies revealed significant (53%) reduction in the degree of spinal cord infarcted after riluzole treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730788     DOI: 10.1097/00001756-199601310-00003

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

Review 1.  Spinal cord injury: a systematic review of current treatment options.

Authors:  David W Cadotte; Michael G Fehlings
Journal:  Clin Orthop Relat Res       Date:  2011-03       Impact factor: 4.176

2.  Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter.

Authors:  S Li; P K Stys
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 3.  Current and future medical therapeutic strategies for the functional repair of spinal cord injury.

Authors:  Tevfik Yılmaz; Erkan Kaptanoğlu
Journal:  World J Orthop       Date:  2015-01-18

Review 4.  A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.

Authors:  Brian K Kwon; Elena Okon; Jessica Hillyer; Cody Mann; Darryl Baptiste; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-04-14       Impact factor: 5.269

Review 5.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study.

Authors:  I Mottet; R Demeure; J Rataud; M Lucas; F Wahl; V Warscotte; J P Thiran; J F Goudemant; B Maldague; J M Maloteaux; J M Stutzmann
Journal:  MAGMA       Date:  1997-09       Impact factor: 2.310

Review 7.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Concise Review: Bridging the Gap: Novel Neuroregenerative and Neuroprotective Strategies in Spinal Cord Injury.

Authors:  Christopher S Ahuja; Michael Fehlings
Journal:  Stem Cells Transl Med       Date:  2016-04-29       Impact factor: 6.940

9.  Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury.

Authors:  Yongchao Wu; Kajana Satkunendrarajah; Yang Teng; Diana S-L Chow; Josef Buttigieg; Michael G Fehlings
Journal:  J Neurotrauma       Date:  2013-03-21       Impact factor: 5.269

Review 10.  Optogenetics applications for treating spinal cord injury.

Authors:  Aftab Ahmad; Sadia Ashraf; Shoji Komai
Journal:  Asian Spine J       Date:  2015-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.